The Oncology Institute Q3 EPS $(0.19) Misses $(0.13) Estimate, Sales $82.03M Beat $74.66M Estimate
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute (NASDAQ:TOI) reported Q3 losses of $(0.19) per share, missing the analyst consensus estimate of $(0.13) by 46.15%. This is a 11.76% decrease over losses from the same period last year. However, the company reported quarterly sales of $82.03 million, beating the analyst consensus estimate of $74.66 million by 9.88%, a 26.25% increase over sales from the same period last year.
November 08, 2023 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The Oncology Institute reported a larger than expected Q3 loss but beat sales estimates. This mixed report may lead to uncertainty in the market.
The Oncology Institute reported a larger than expected loss for Q3, which is negative for the stock. However, they also reported higher than expected sales, which is positive. The mixed nature of this report may lead to uncertainty in the market, making it difficult to predict the short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100